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Gene polymorphismAbstract Introduction: Atherosclerosis is partly a heritable disorder. Various genetic polymor-
phisms have been linked to the atherosclerotic process and its complications. Glu298Asp polymor-
phism of endothelial nitric oxide synthase gene is one such genetic marker for atherosclerosis.
Aim of the work: To study the relationship between endothelial nitric oxide synthase gene polymor-
phism and atherosclerotic coronary and carotid arterial disease in Egyptian population.
Patients and methods: Our study included 95 Egyptian patients with Egyptian father and mother,
classiﬁed into two groups: Group 1; 63 patients with ischemic heart disease and Group 2; 32 control
subjects and subjected to careful history taking, thorough clinical examination, standard twelve-
lead surface electrocardiogram, routine laboratory investigations, echo Doppler study, carotid arte-
rial duplex, invasive coronary angiography and analysis of the endothelial NOS3 gene polymor-
phism using PCR–RFLP for detection of different genotype variants (Glu/Glu (GG), Glu/Asp
(GT) and Asp/Asp (TT) genotype).
Conclusion: Glu298Asp polymorphism in the endothelial nitric oxide synthase gene did not
increase the susceptibility to coronary and carotid arteries disease in the studied patients.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Atherosclerosis, a chronic inﬂammatory disease, underlies the
pathogenesis of coronary artery disease (CAD). The molecular
etiology of coronary atherosclerosis involves interaction of
many genes and environmental factors.22 Nitric oxide (NO)
226 H. Younan et al.produced by the enzyme endothelial nitric oxide synthase
(eNOS), has critical roles in the regulation of vascular homeo-
stasis and prevention of atherogenesis by inhibiting leukocyte,
platelet activation and smooth muscle cell proliferation.17
Polymorphisms of eNOS gene were shown to be associated
with CAD in some populations.8 The guanine to thymine
(Glu298Asp) polymorphism at position 894 of the eNOS gene
(replacement of glutamate (G) by aspartate (T)) is under exten-
sive study and T allele had been described as susceptibility al-
lele for CAD in some studies.28 There have been conﬂicting
reports on the relationship between this polymorphism and
CAD from studies done in various ethnic groups across the
world.11,8 Therefore, we undertook the current study to inves-
tigate whether the eNOS Glu298Asp polymorphism is related
to coronary and carotid arterial disease.
2. Aim of the work
To study the relationship between endothelial nitric oxide syn-
thase gene polymorphism and atherosclerotic coronary and
carotid arterial disease in Egyptian population.
3. Patients and methods
Our study included 63 patients consecutively admitted to our
Institute (Fayoum University Hospital) and had angiographi-
cally deﬁned CAD (>50% stenosis affecting at least one
coronary vessel) and 32 individuals with normal coronary
angiography. Inclusion criteria: All patients and controls were
from the Egyptian population with Egyptian father and
mother. Exclusion criteria: Acute renal failure, history of
severe contrast reaction, uncontrolled infection, active bleed-
ing, severe hypertension, coagulopathy (INR> 1.8) and pa-
tients of non Egyptian population or with non Egyptian
father or mother.
3.1. Each patient included in the study was subjected to
1. Careful history taking and thorough physical examination.
2. Standard twelve-lead electrocardiogram (12-lead ECG):
For the assessment of cardiac rhythm, features suggesting
myocardial ischemia (ST segment and T wave abnormali-
ties and pathological Q waves), and voltage criteria of left
ventricular hypertrophy.
3. Routine laboratory testing: Complete blood picture, fasting
plasma glucose, blood urea, serum creatinine, SGOT,
SGPT, PT, INR and complete lipid proﬁle.
4. Echocardiography study: Both patients and control subject
were studied by trans-thoracic echocardiography using a
commercially available echocardiographic mach-
ines (Siemens), equipped with 3.5 MHz phased array trans-
ducer. M-mode echocardiography was used to assess cham-
ber dimensions and calculation of the ejection fraction.
Two dimensional echocardiography for the assessment of
the overall ventricular systolic function by eyeballing and
biplane Simpson’s rule, assessment of the LV end-diastolic
and systolic dimensions of regional wall motion abnormal-
ities, valvular thickening, calciﬁcation, pericardial effusion
or thickening and to rule out intra-cardiac masses or
thrombi. Trans-mitral pulsed wave Doppler to measure
peak E velocity, peak A velocity and the E/A ratio.5. Carotid arterial duplex: High resolution B mode, color
Doppler and pulse Doppler ultrasonography of both caro-
tid arteries were performed with an ultrasound machine:
General Electric (GE) (Logic 7) equipped with 4–11 MHz
linear array transducer and centralized reading was per-
formed by one trained reader blinded to subject’s character-
istics and according to a standardized protocol. Patients
were examined in the supine position with the head tilted
backwards. After the carotid arteries were located by trans-
verse scans the probe was rotated 90 to obtain and record
a longitudinal image of the anterior and posterior walls.
The maximum cIMT measured at the near and far walls
of the right and left CCAs was scanned at least 1.5 cm prox-
imal to the origin of the bulb (deﬁned as the point of diver-
gence of the walls of the CCAs). For each side, at least one
optimal longitudinal image was frozen in end-diastole by
electrocardiogram R-triggering. The IMT was measured
only at a plaque-free site, along a 10 mm segment of the
far wall of the CCA and measured as the distance between
the lumen–intimal interface and the media–adventitia inter-
face using an automated edge detection algorithm. The
mean cutoff cIMT value was 0.89 mm. Image showing the
maximum intimal-media thickness was stored and the aver-
age values were considered. For visualized plaques, the
maximum diameter was determined and included in further
analysis. The presence of plaques was deﬁned as localized
echo structures encroaching into the vessel lumen for which
the wall thickening was at least 50% greater than that of
the surrounding vessel wall. Furthermore, the grade of ste-
nosis in the carotid and vertebral arteries was assessed
through the increase in the peak systolic and end-diastolic
velocities.24
6. Coronary Angiography was done to all patients via a retro-
grade transfemoral approach, using Seldinger’s technique.
The angiograms were done in all standard views using right
and left coronary catheters with the assessment of the num-
ber of diseased vessels, sites of lesions and estimation of the
severity of stenosis.
7. Analysis of the endothelial NOS3 gene polymorphism:
Three milliliters (3 ml) venous blood samples were with-
drawn from subjects under aseptic conditions into sterile
EDTA vacutainer tubes for DNA extraction. The samples
were stored at200C. The test was done in ﬁve main steps:
 Extraction of genomic DNA from peripheral blood
leucocytes of EDTA anti-coagulated blood.
 Ampliﬁcation of the extracted DNA.
 Detection of PCR ampliﬁcation products using agarose
gel electrophoresis.
 The ampliﬁed products were digested with (MboI) res-
triction enzyme.
 The digested products were then analyzed by electro-
phoresis on agarose gel containing ethidium bromide
and visualized by ultraviolet light transillumination for
determination of Glu298ﬁ Asp endothelial nitric oxide
synthase genotypes.4. Statistical analysis
Collected data were computerized and analyzed using the
Statistical Package for Social Science (SPSS) version 16.
Table 1 Gender distribution in both groups.
Group Total
Group 1 Group 2
Sex
Male N 47 15 62
% 74.6 46.9 65.3
Female N 16 17 33
% 25.4 53.1 34.7
Total N 63 32 95
% 100 100 100
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proportion for qualitative variables, mean SD and range for
Quantitative variables. Comparison between groups was done
using the Chi-Square test for qualitative variables, independent
t-test and ANOVA test for quantitative variables. Pearson cor-
relation was done between two quantitative variables to test
association between variables. P values with signiﬁcance of less
than 5% were considered statistically signiﬁcant.
5. Results
5.1. Baseline characteristics
Our study included 63 patients with coronary artery disease
(group 1) and 32 age- and sex-matched subjects with normal
coronary angiography (group 2). In group 1: 16 patients were
females (25.4%) and 47 were males (74.6%), their age ranged
between 30 and 67 years with mean age and standard deviation
(SD) 51.71 ± 8.97 years. In group 2: 17 patients were females
(53.1%) and 15 were males (46.9%), their age ranged between
20 and 70 years with mean age and SD 46.97 ± 11.11 years.
There was a signiﬁcant differences in the prevalence of male
gender (P value = 0.027), smoking (P= 0.049), DM (P va-
lue = 0.008), and hypertension (P value = 0.044). There was
no signiﬁcant difference in the prevalence of family history
for CAD (P value = 0.293), obesity (P value = 0.17) between
the patients and controls. There was a highly signiﬁcant level
of total cholesterol, LDL, triglyceride (P value = <0.0001)
and FBS levels (P value = 0.003) in patients of group 1 when
compared to the control group as shown in Tables 1–3.
5.2. Genotype distribution in the studied population
In group 1: 63.5% of the patients (n= 40) were GG genotype,
33.3% of the patients (n= 21) were GT genotype and 3.2% of
the patients (n= 2) were TT genotype. In group 2: 53.1% of
the control group (n= 17) were GG genotype, 43.8% (n= 14)
were GT genotype and 3.1% (n= 1) were TT genotype. There
was no signiﬁcant statistical difference in the genotype distribu-
tion of GG genotype, GT genotype and TT genotype between
group 1 and 2 (P value = 0.605). There was no signiﬁcant statis-
tical difference in the G and T allele frequency between group 1
and 2 (P value = 0.531) as shown in Table 4.
In Group 1: 59.6% (n= 28) of males were GG genotype
and 38.3% (n= 18) were GT genotype and 2.1% (n= 1) were
TT genotype. On the other hand 75% (n= 12) of females were
GG genotype and 18.8% (n= 3) were GT genotype and 6.2%
(n= 1) were TT genotype. There was no signiﬁcant statistical
difference the genotype frequency in males and females (P va-
lue = 0.29). There was no signiﬁcant statistical difference in
the genotype distribution between smokers and non smokers
(P value = 0.35), diabetic and non diabetic (P value = 0.16),
hypertensive and normotensive (P value = 0.45), patients with
and without family history of CAD (P value = 0.68). There
was signiﬁcantly higher GT and TT genotype in obese patients
when compared to non obese (P value = 0.015). There was no
signiﬁcant statistical difference in the genotype distribution be-
tween patients presented with and without acute STEMI (P va-
lue = 0.35). There was no signiﬁcant statistical difference in
the genotype distribution between patients with impaired LV
systolic function when compared to patients with normal LVsystolic function (P value = 0.08).There was no signiﬁcant sta-
tistical difference in the genotype distribution of patients with
single vessel disease when compared to patients with two vessel
and multi vessel coronary artery disease (P value = 0.38) as
shown in Tables 4–9.
5.3. Carotid intima media thickness
Our study included 96 patients examined by carotid Doppler and
cIMT was measured bilaterally. There was highly signiﬁcant
cIMT in male patients (P value = 0.008), diabetic (P va-
lue = 0.006), hypertensive (P value = 0.006), patients with
hypercholesterolemia (P value = 0.003) and patients with CAD
compared to those with normal coronaries (1.060 ± 0.1386 vs.
0.809 ± 0.1634, P value =<0.0001). The cIMT was not signif-
icantly increased in patients with endothelial nitric oxide synthase
enzyme gene polymorphism(GG,0.981 ± 0.1807;GT,0.977 ±
0.2001;TT,0.867 ± 0.2517; P value = 0.599) and there was no
signiﬁcant difference in the G and T allele frequency in patients
with higher cIMT when compared to patients with normal cIMT
(P value = 0.8) as shown in Tables 10 and 11.
6. Discussion
In addition to established risk factors, genetic factors may
have important role in the pathogenesis of coronary athero-
sclerosis. Using the approach of epidemiological studies; it is
possible to identify weak susceptible genes in polygenic dis-
eases like coronary heart disease.33 Due to the protective roles
of NO against important events during atherogenesis, the
NOS3 gene has been identiﬁed as having roles in deciding sus-
ceptibility to coronary heart disease.20,35
Glu298Asp polymorphism of endothelial nitric oxide syn-
thase gene is one such genetic marker for atherosclerosis that
has been extensively studied across the world. The
Glu298ﬁ Asp Endothelial Nitric Oxide Synthase gene poly-
morphism, with the substitution of G by T (replacement of
glutamate by aspartate) at nucleotide position 894 in exon 7 re-
duces the activity of the enzyme, thereby resulting in a decrease
in the production of nitric oxide.19,26 Therefore, the Glu298Asp
polymorphism may predispose the individual to an increased
risk for atherosclerosis and its complications. There have been
conﬂicting reports on the relationship between this polymor-
phism and coronary artery disease, functional changes in the
endothelium and carotid intima-media thickness (cIMT) from
studies done in various ethnic groups across the world.18,32
Our study included 63 patients who had angiographically
deﬁned coronary artery disease (>50% stenosis affecting at
Table 2 Distribution of different CAD risk factors in both groups.
Parameters Group 1 (N= 63) (%) Group 2(N= 32) (%) P value Signiﬁcance
Smoking Yes 49.2 28.1 0.049 S
No 50.8 71.9
DM Yes 34.9 9.4 0.008 S
No 65.1 90.6
HTN Yes 42.9 21.9 0.044 S
No 57.1 78.1
BMI Yes 49.2 34.4 0.17 NS
No 50.8 65.6
FH Yes 17.5 9.4 0.293 NS
No 82.5 90.6
Table 3 The mean values of lipid proﬁle and FBS in both groups.
Parameter Group 1 Group 2 P value Signiﬁcance
Total cholesterol (mg/dl) 228.14 ± 69.18 160.47 ± 40.52 0.0001 HS
LDL (mg/dl) 156.92 ± 65.09 97.78 ± 32.05 0.0001 HS
HDL (mg/dl) 33.70 ± 13.93 35.25 ± 3.282 0.537 NS
TG (mg/dl) 192.08 ± 70.46 139.50 ± 52.65 0.0001 HS
FBS(mg/dl) 125.32 ± 50.69 95.41 ± 32.82 0.003 S
Table 4 G and T allele frequency in both groups.
Group Total
Group 1 Group 2
Allele
G N 101 48 149
% 67.8 32.2 100
T N 25 16 41
% 60.9 39.1 100
Total N 126 64 190
% 100 100 100
228 H. Younan et al.least one coronary vessel) and 32 individuals with normal
coronary angiograms as the control group. All patients and
controls were from the Egyptian population with Egyptian
father and mother. Our study showed that the heterozygous
and homozygous Asp mutants were not signiﬁcantly associ-
ated with the occurrence of coronary artery disease. 63.5%
of CAD patients were Glu/Glu (GG) genotype, 33.3% were
Glu/Asp (GT) genotype and 3.2% were Asp/Asp (TT)
genotype while in the control group, 53.1% of were Glu/GluTable 5 Genotype distribution in group 1.
Sex
Male N
%
Female N
%
Total N
%genotype, 43.8% were Glu/Asp genotype and 3.1% of the con-
trol group were Asp/Asp genotype (P value = 0.605).
Our results came in agreement with case control studies
done in Taiwan and Korea and found no evidence of associ-
ation between the Asp variant of the endothelial nitric oxide
synthase enzyme gene and coronary artery disease.35,16 On
the other hand12 in UK population showed that Asp298
homozygosity was signiﬁcantly associated with angiographic
CAD, the frequency of the Asp homozygous and the T allele,
in the case and control groups were (35.9% and 47.8%, vs.
10.2% and 31.2%, respectively, P< 0.0001).2 Found signiﬁ-
cantly higher Asp/Asp carriers (Asp homozygotes) in coro-
nary artery disease patients when compared to the normal
control (15.9% vs. 6.1%, P value = 0.01)36,5 reported posi-
tive association between endothelial nitric oxide synthase
enzyme gene polymorphism and the occurrence of coronary
artery disease.
Our study revealed no signiﬁcant difference in the distribu-
tion of the T allele and G allele in patients with CAD com-
pared to the control group (27.4 vs. 32.6 and 72.6% vs.
67.4%, P value = 0.531). Our results came in agreement
with6,9 in the Australian Caucasian population who found
no association between endothelial nitric oxide synthaseGenotype Total
GG GT TT
28 18 1 47
59.6 38.3 2.1 100
12 3 1 16
75 18.8 6.2 100
40 21 2 63
63.5 33.3 3.2 100
Table 6 Genotype distribution among different risk factors in
group 1.
Genotype Total
GG GT TT
Smokers
Yes N 17 13 1 31
% 54.9 41.9 3.2 100
No N 23 8 1 32
% 71.9 25 3.1 100
Total N 40 21 2 63
% 63.5 33.3 3.2 100
Diabetics
Yes N 14 7 2 23
% 60.9 30.4 8.7 100
No N 26 14 0 40
% 65 35 0 100
Total N 40 21 2 63
% 63.5 33.3 3.2 100
HTN
Yes N 18 9 0 27
% 66.7 33.3 0 100
No N 22 12 2 36
% 61.1 33.3 5.6 100
Total N 40 21 2 36
% 63.5 33.3 3.2 100
Family history
Yes N 8 3 0 11
% 72.7 27.3 0 100
No N 32 18 2 52
% 61.5 34.6 3.8 100
Total N 40 21 2 63
% 63.5 33.3 3.2 100
Obesity
Yes N 25 6 0 31
% 80.6 19.4 0 100
No N 15 15 2 32
% 46.9 46.9 6.2 100
Total N 40 21 2 63
% 63.5 33.3 3.2 100
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artery disease. Also34,16 found no association between the fre-
quency of T allele and coronary artery disease in Taiwan and
Korean population. On the other hand12 showed that T allele
was signiﬁcantly associated with angiographic coronary artery
disease (P value < 0.0001).Table 7 Genotype in patients with and without acute STEMI in gr
With acu
Genotype
GG N 21
% 67.7
GT N 10
% 32.3
TT N 0
% 0
Total N 31
% 100In our study, the severity of coronary artery disease was not
signiﬁcantly associated with the heterozygous and homozy-
gous Asp mutants (P value = 0.38). Our results came in agree-
ment with6,9 in the Australian Caucasian population who
found no association between the frequency of the T allele
and the severity of coronary artery disease.9 On the other
hand2 observed an association between the T7863C polymor-
phism and the Duke scoring system, a prognostic index that
considers not only the number of stenosed vessels but also
the percentage of narrowing of the major vessels and the ana-
tomical localization of the stenosis.
Subgroup analysis of our study revealed that the Asp vari-
ant was not signiﬁcantly associated with male sex (P va-
lue = 0.4), hypertension (P value = 0.45), diabetes mellitus
(P value = 0.16), smoking (P value = 0.35) and positive fam-
ily history for CAD15 showed that the association between
CAD and the Asp variant was not signiﬁcant in any of the sub-
groups of CAD patients based on age, sex, status of hyperten-
sion, diabetes and smoking positive family history for CAD.
On the other hand13 showed that Asp allele occurred more fre-
quently in the subgroups of CAD patients: diabetes mellitus
(P< 0.001), smoking (P< 0.001), hypertension (P= 0.03),
family history of coronary artery disease (P= 0.02) and dysl-
ipidemia (P= 0.02).
Our results suggested that the heterozygous and homozy-
gous Asp mutants were signiﬁcantly associated with increased
body mass index (P value = 0.015). Our results came in agree-
ment with.12 On the other hand in the Australian Caucasian
population, the T allele frequency was not associated with in-
creased body mass index.6,9
Our study results showed that the heterozygous and homo-
zygous Asp mutants were not signiﬁcantly associated with the
occurrence of acute STEMI (P value = 0.35). Our results
came in agreement with13 who concluded that the Glu298ASP
polymorphism of the endothelial nitric oxide synthase
gene is associated with STEMI in Mexican population.
Similarly11,12,15 demonstrated possible correlations between
the endothelial nitric oxide synthase enzyme gene polymorphism
Glu298Asp and acute ST elevation myocardial infarction.
Our study results showed that the heterozygous and
homozygous Asp mutants were not signiﬁcantly associated
with the occurrence of left ventricular systolic dysfunction
(P value = 0.085). Our results came in agreement with15 who
showed signiﬁcant association between Asp mutant and acute
STEMI and development of left ventricular systolic dysfunc-
tion. Similarly32 demonstrated possible correlations between
the endothelial nitric oxide synthase enzyme gene polymor-
phism Glu298Asp and left ventricular dysfunction.oup 1.
te STEMI Without acute STEMI Total
17 38
53.1 60.3
14 24
43.8 38.1
1 1
3.1 1.6
32 63
100 100
Table 8 Genotype in patients with impaired systolic function and patients with normal LV systolic function in group 1.
Impaired systolic function Normal systolic function Total
Genotype
GG N 13 27 40
% 65 62.8 63.5
GT N 5 16 21
% 25 37.2 33.3
TT N 2 0 2
% 10 0 3.2
Total N 20 43 63
% 100 100 100
Table 9 Genotype and number of coronary vessels involved.
One vessel Two vessels Multi vessels Total
Genotype
GG N 18 8 14 40
% 64.3 61.5 63.6 63.5
GT N 10 5 6 21
% 27.3 38.5 27.3 33.3
TT N 0 0 2 2
% 0 0 9.1 3.2
Total N 28 13 22 63
% 100 100 100 100
Table 10 Genotype and cIMT and genotype.
cIMT Total
Normal Thickened
Genotype
GG N 23 34 57
% 57.5 61.8 60
GT N 15 20 35
% 37.5 36.4 36.8
TT N 2 1 3
% 5 1.8 3.2
Total N 40 55 95
% 100 100 100
Table 11 Genotype and cIMT.
cIMT Total
Normal Thickened
Genotype
G N 61 88 149
% 40.9 59.1 100
T N 19 22 41
% 46.3 53.7 100
Total N 40 55 190
% 100 100 100
230 H. Younan et al.Carotid intima-media thickness (cIMT) has been widely
used as a surrogate marker of atherosclerotic disease31, may
predict the risk of cardiac events as myocardial infarction,
angina pectoris and repeated coronary intervention5 and theinvolvement of other arterial beds with atherosclerosis.23
Several genetic variants have been examined in relation to
carotid atherosclerosis, more often by association than by
linkage analysis.10,21,3 27 observed paradoxical increase in
the carotid arterial wall thickness and hyperplasic response
of the arterial wall in response to carotid artery ligation in
eNOS-mutant mice, indicating that a primary defect in the
NOS/NO pathway may promote abnormal remodeling and
pathologic changes in vessel wall morphology associated with
atherosclerosis.
Our study revealed signiﬁcantly higher cIMT in males, dia-
betic, hypertensive and patients with high total cholesterol and
LDL levels. Our results came in agreement with1 who showed
that male gender (P= 0.006), older age (P< 0.001), smoking
habit (0.002), hypertension (P= 0.002), diabetes mellitus
(P= 0.062), high triglycerides level (P= 0.019) and impaired
fasting blood glucose level (P= 0.036) are related to greater
cIMT values. Similarly4 showed that cIMT is associated with
increasing age, male gender, high SBP, high LDL-C, current
smoking, impaired fasting glucose and diabetes mellitus.
Our study showed that cIMT signiﬁcantly increased in pa-
tients with coronary artery disease compared to those with nor-
mal coronaries (cIMT 1.060 ± 0.1386 vs. 0.809 ± 0.1634 mm,
P value =<0.0001).Our results came in agreement with29 who
reported good sensitivity of increased cIMT in predicting the
risk of coronary artery disease and cardiac events. On the other
hand,7,14 reported no sensitivity of increased cIMT in predict-
ing the presence of coronary artery disease.
Our study suggested that endothelial nitric oxide synthase
enzyme gene polymorphism is not associated with increased
cIMT (Glu/Glu: 0.981 ± 0.1807 mm, Glu/Asp: 0.977 ±
0.2001 mm, Asp/Asp: 0.867 ± 0.2517 mm; P value = 0.599)
and Asp variant was not signiﬁcantly associated with in-
creased cIMT (P value = 0.8). Our results came in agreement
with 30 who found no association between increased cIMT
and endothelial nitric oxide synthase enzyme gene polymor-
phism (average cIMT: Asp/Asp: 0.77 ± 0.11 mm; Glu/Glu
and Glu/Asp: 0.80 ± 0.12 mm, P=NS) .On the other
hand25 found signiﬁcantly greater cIMT in patients with
Asp/Asp genotype displayed a (Asp/Asp: 0.45 ± 0.03 mm,
Glu/Glu: 0.37 ± 0.1 mm, Glu/Asp: 0.35 ± 0.1 mm,
P= 0.0002).
Several issues could account for discrepancy in the results
of endothelial nitric oxide synthase gene polymorphism
in our study compared to other clinical studies especially
random type I errors in positive studies; lack of power in neg-
ative studies; population stratiﬁcation; genetic heterogeneity;
Relationship of eNOS gene polymorphism with atherosclerotic coronary and CAD 231gene–environment interactions modulating gene regulation
and expression.7. Study limitations and recommendations
In our study, ethnic admixture was minimized to the maximum
possible extent by including only individuals of Egyptian ori-
gin. We performed our study on a small sample of coronary
artery disease patients from Fayoum City and our results sug-
gest that polymorphism of Glu2983Asp and T7863C of the
eNOS gene does not increase the susceptibility to coronary
and carotid arteries disease in the studied patients.
Further studies are warranted with larger sample size to
investigate whether polymorphisms of the eNOS gene, both
alone and in combination with the endothelial NO function,
could represent a useful genetic markers for identifying Egyp-
tian individuals at risk for the development of coronary and
carotid arteries disease.
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